Research and Markets (http://www.researchandmarkets.com/research/cm2s97/tnfalpha)
has announced the addition of the "TNF-Alpha
Signaling Pathway in Oncology Drug Pipeline Update 2014" report
to their offering.
The TNF-alpha signaling pathway stimulates the MAPK signaling module and
There are today 359 companies plus partners developing 531 TNF-alpha
pathway targeting drugs in 1960 developmental projects in cancer. In
addition, there are 7 suspended drugs and the accumulated number of
ceased drugs over the last years amount to another 250 drugs.
TNF-Alpha Signaling Pathway In Oncology Drug Pipeline Update lists all
drugs and gives you a progress analysis on each one of them. Identified
drugs are linked to 247 different targets. All included targets have
been ross-referenced for the presence of mutations associated with
human cancer. To date 243 out of the 245 studied drug targets so far
have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links
out to the mutational analysis for each of the drug targets for detailed
information. All drugs targets are further categorized on in the
software application by 54 classifications of molecular function and
with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Drug name & Synonyms
Pipeline Breakdown According to Number of Drugs
For more information visit http://www.researchandmarkets.com/research/cm2s97/tnfalpha.
[ Back To NFVZone's Homepage ]